Ex Vivo Gene-editing Platforms for T Cells
The U CAR-T platform aims to develop innovative therapies for cancer patients.
It aims to remove the immunological rejection molecules on the T cells of a healthy donor through gene editing, and transform such molecules via CAR to prepare off-the-shelf allogeneic CAR-T to treat patients.
Advantages of the Platform
- Off the shelf
- Better quality product from a healthy donor
- More effective quality control
- Uniformity of products
- Flexible clinical application
- Low costs
In February 2022, EdiGene announced a non-exclusive, worldwide license agreement with Arbor Biotechnologies to access Arbor’s proprietary CRISPR gene editing technology for certain ex vivo engineered cell therapy programs in the field of oncology.